<DOC>
	<DOC>NCT02736474</DOC>
	<brief_summary>The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.</brief_summary>
	<brief_title>Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia</brief_title>
	<detailed_description>This is a randomized, double-blind, and placebo-controlled study. Subjects with evaluation and confirmation that inclusion and exclusion criteria are met, will be treated with naltrexone sustained release 15mg once per day and bupropion sustained release 150mg once per day in the first two weeks, and naltrexone 25mg once per day and bupropion 300mg once per day during the rest of the study.The purpose of this research is to observe the efficacy of Naltrexone and Bupropion on weight loss and smoking cessation compared to placebo.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Bupropion hydrochloride, naltrexone hydrochoride drug combination</mesh_term>
	<criteria>Diagnosis of schizophrenia; On stable atypical antipsychotic medication regimen for at least one month; BMI &gt; 28 kg/m2 using the BMI criterion for obesity in the Chinese population; Smoking at least 10 cigarettes daily for a minimum of 1 year; Desire to lose weight and quit smoking. Binge eating or other eating disorders; Current use of weight loss or antidiabetic medications; Current substance use (except nicotine or caffeine); Elevated hepatic transaminase levels (&gt;2.5x normal range); Clinically significant Thyroid Stimulating Hormone（TSH） and/or thyroxine4（T4） abnormalities; History of seizure disorder; History of unstable cardiac problems or other unstable medication conditions; Being pregnant or nursing (for women).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>